Rational Pharmacotherapy in Cardiology

Advanced search


Full Text:


About 150 million men worldwide and about 50% of men aged 40-88 y.o. in outpatient practice suffer from erectile dysfunction (ED). There is a linear relation between the age and ED rate. The main reason of ED in the majority of men (about 80% of patients) is cardiovascular diseases (atherosclerosis, hypertension, diabetes mellitus), as well as certain risk factors (smoking, alcohol abuse, physical inactivity etc.). The problem of ED in cardiac outpatients and modern pharmacotherapy is discussed. The phosphodiesterase-5 (PDE5) inhibitors increase the relaxing effect of nitric oxide and increase cyclic GMP levels during sexual arousal. It results in increase of cavernosum blood flow, contributing to the physiological erection. Three PDE5 inhibitors (sildenafil, tadalafil, vardenafil) are used in clinical practice nowadays.

About the Authors

M. N. Mamedov
State Research Center for Preventive Medicine
Russian Federation
Petroverigsky per. 10, Moscow, 101990

G. G. Sharvadze
State Research Center for Preventive Medicine
Russian Federation
Petroverigsky per. 10, Moscow, 101990

E. A. Poddubsky
State Research Center for Preventive Medicine
Russian Federation
Petroverigsky per. 10, Moscow, 101990

A. K. Ausheva
State Research Center for Preventive Medicine
Russian Federation
Petroverigsky per. 10, Moscow, 101990


1. Oganov R.G., Maslennikova G.Ya. Cardiology progress in Russia. Cardiovascular therapy and prevention 2004; 3 (Pt 1): 11-14. Russian. (Оганов Р.Г., Масленникова Г.Я. Развитие профилактической кардиологии в России. Кардиоваскулярная терапия и профилактика 2004; 3 (часть 1): 11-14).

2. Mamedov M.N. Strategy of a unified approach to diagnosis and treatment of erectile dysfunction, androgen-deficient state and cardiovascular disease. M.: Meditsinskaya kniga; 2009. Russian. (Мамедов М.Н. Стратегия единого подхода к диагностике и лечению эректильной дисфункции, андроген-дефицитного состояния и сердечно-сосудистых заболеваний. М.: Медицинская книга; 2009).

3. Oganov R.G., Mamedov M.N. School on the diagnosis and treatment of metabolic syndrome. Manual for physicians. M.: Meditsinskaya kniga; 2007. Russian. (Оганов Р.Г., Мамедов М.Н. Школа по диагностике и лечению метаболического синдрома. Пособие для врачей. М.: Медицинская книга; 2007).

4. Pritzker M.R. The penile stress test: a window to the hearts of man (Abstract). Circulation 1999;100(Suppl I):I711.

5. Roumegère T., Bollens R., Wespes E. et al. Prevalence of hyperlipidemia and risk of coronary heart disease in a population with erectile dysfunction. J Urol 2001; 165 (5 Suppl): 700.

6. Braun M., Wassmer G., Klotz T. et al. Epideminology of erectile dysfunction:results of the „Cologne Male Survey“. Int J Impot Res 2000;12(6):305-11.

7. Guay A.T., Perez J.B., Jacobson J. et al. Efficacy and safety of Sildenafil citrate for treatment of erectile dysfunction in a population with associated organic risk factors. Journal of Andrology 2001; 22(5): 793-797.

8. Mazo E.B., Gamidov S.I., Iremashvili V.V. Erectile dysfunction. M.: MIA; 2004. Russian. (Мазо Е.Б., Гамидов С.И., Иремашвили В.В. Эректильная дисфунция. М.: МИА; 2004).

9. Fonseca V., Jawa A. Endothelial and erectile dysfunction, diabetes mellitus, and the metabolic syndrome: common pathways and treatments? Am J Cardiol 2005; 96(12B):13M-18M.

10. Feldman H.A., Goldstein I., Hatzichristou D.G. et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994; 151(1): 54-61.

11. McKinlay J.B. Theworldwide prevalence and epidemiology of erectile dysfunction. IntJImpot Res 2000; 12 Suppl 4:S6-S11.

12. Melman A., Gingell J.C. The epidemiology and pathophysiology of erectile dysfunction. J Urol 1999; 161(1): 5-11.

13. Bortolotti A., Parazzini F., Colli E., Landoni M. The epidemiology of erectile dysfunction and its risk factors. Int J Androl 1997; 20(6): 323-328.

14. Montorsi F. Assessment, diagnosis, and investigation of erectile dysfunction. Clin Cornerstone 2005; 7(1):29-35.

15. Montorsi F., Briganti A., Salonia A. et al. Erectile dysfunction prevalence, time of onset and association with risk factors in 300 consecutive patients with acute chest pain and angiographically documented coronary artery disease. Eur Urol 2003; 44(3):360-5.

16. Mulhall J., Althof S.E., Brock G.B. et al. Erectile dysfunction: monitoring response to treatment in clinical practice-recommendations of an international study panel. J Sex Med 2007; 4(2): 448-64.

17. VertkinA.L., PushkarD.Yu., Topolyanskiy A.V., Segal A.S. Erectile dysfunction. Lechashchiy vrach 2003; 7: 1-4. Russian. (Верткин А.Л., Пушкарь Д.Ю., Тополянский А.В., Сегал А.С. Эректильная дисфункция. Лечащий врач 2003; 7: 1-4).

18. Francis S.H., Corbin J.D. Molecular mechanisms and pharmacokinetics of phosphodiesterase-5 antagonists. Curr Urol Rep 2003;4(6):457-65.

19. Rotella D.P. Phosphodiesterase 5 inhibitors: current status and potential applications. Nat Rev Drug Discov 2002; 1(9): 674-682.

20. Claes H., Van Poppel H. The use of sildenafil, tadalafil, and vardenafil in clinical practice. J Sex Med 2004; 1(suppl 1):42. Abstract O43.

21. Goldstein I., Lue T.F., Padma-Nathan H. et al. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med 1998;338(20):1397-404.

22. Markou S., Perimenis P., Gyftopoulos K. et al. Vardenafil (Levitra) for erectile dysfunction: a systematic review and meta-analysis of clinical trial reports. Int J Impot Res 2004;16(6):470-8.

23. Gamidov SI, Sotnikova EM, Gasanov RV. Prevention of erectile dysfunction in patients with metabolic syndrome. Urologiia 2007;(5):44-8. Russian. (Гамидов С.И., Сотникова Е.М., Гасанов Р.В.Профилактика эректильной дисфункции у больных с метаболическим синдромом. Урология 2007; 5: 44-49).

24. Saenz de Tejada I., Angulo J., Cuevas P. et al. The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil. Int J Impot Res 2001;13(5):282-90.

25. DeBusk R., Drory Y., Goldstein I. et al. Management of sexual dysfunction in patients with cardiovascular disease: recommendations of the Princeton Consensus Panel. Am J Cardiol 2000; 86 (2A): 62F-68F.

26. Kostis J.B., Jackson G., Rosen R. et al. Sexual dysfunction and cardiac risk: the 2nd Princeton Consensus Conference. Am J Cardiol 2005; 96(2): 313-321.

27. Thadani U., Smith W., Nash S. et al. The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease. J Am Coll Cardiol 2002;40(11): 2006-12.

28. Kloner R.A., Jarow J.P. Erectile dysfunction and sildenafil citrate and cardiologist. Am J Cardiol 1999;83(4):576-82, A7.

29. WebbD.J., Freestone S., Allen M.J., Muirhead G.J. Sildenafil citrate and blood pressure-lowering drugs: results of drug interaction studies with an organic nitrate and a calcium antagonist. Am J Cardiol 1999;83(5A):21C-28C.

30. Grimm R.H. Jr, Grandits G.A., Prineas R.J. et al. Long–term effects on sexual function of five antihypertensive drugs and nutritional hygenic treatment in hypertensive men and women: treatment of mild hypertension study (TOMHS). Hypertension 1997; 29 (1 Pt 1): 8–14.

31. Wassertheil-Smoller S., Blaufox M.D., Oberman A.S. et al. The trial of antihypertensive interventions and management (TAIM) study. Adequate weight loss, alone and combined with drug therapy in the treatment of mild hypertension. Arch Intern Med 1992; 152(1): 131-6.

32. Müller S.C., el-Damanhoury H., Rüth J., Lue T.F. Hypertension and impotence. Eur Urol 1991; 19(1): 29-34.

33. Rosen R.C., Weiner D.N. Cardiovascular disease and sleep-related erections. J Psychosom Res 1997;42(6):517-30.

34. Rizvi K., Hampson J.P., Harvey J.N. Do lipid-lowering drugs cause erectile dysfunction? A systematic review. Fam Pract 2002;19(1):95-8.

For citation:

Mamedov M.N., Sharvadze G.G., Poddubsky E.A., Ausheva A.K. PHOSPHODIESTERASE-5 INHIBITORS USE IN PATIENTS WITH ERECTILE DYSFUNCTION AND CARDIOVASCULAR DISEASE IN CLINICAL PRACTICE. Rational Pharmacotherapy in Cardiology. 2010;6(5):691-696. (In Russ.)

Views: 320

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)